Vote ReNetX Bio
Erika R. Smith
City/Town where Organization Located
Company/organization description (<500 characters)
ReNetx Bio – a clinical stage company established to provide first-in-class therapeutics to treat damage to the central nervous system (CNS). The company's scientific founder, Dr. Stephen Strittmatter from Yale University, identified key factors that inhibit regrowth in the CNS. The company's novel protein therapeutic approach binds these inhibitors thereby enabling nerve fiber regrowth and increased synaptic plasticity for neural reconnection. ReNetX Bio has raised $25M, launched a Phase 1/2 clinical trial proof of concept trial and was granted "Fast Track Designation" from FDA.
Tell us about the milestones your venture accomplished in 2019, eg., key team members added, revenue level achieved, major sales made or endorsements received, successful exit, etc... (<500 characters)
Fast Track Designation, FDA approval and Launch of Clinical Trial Phase 1/2 study for spinal cord injury, License from major biotech
Stage: Does your venture generate revenue? YES or NO
What CT entrepreneur ecosystem resources (spaces, programs, events, schools, etc.) have helped you succeed? (<500 characters)
Yale, BioCT, Connecticut Innovations
What people are saying about ReNetX Bio...
Changing lives through the REstoration of neural NETworks. Our mission is to provide first-in-class therapeutics to treat injury/damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke, and glaucoma. ?The company was founded based on the innovative technology from Dr. Stephen Strittmatter's work at Yale University to improve neurologic function after CNS injury – creating a significant and completely unmet need estimated at >$5B annually. The technology allows neurons to regrow by eliminating factors that inhibit growth. This technology platform could help to restore function in patients who are suffering from spinal cord injuries, stroke, and glaucoma. Bill Kenney